MESOBLAST LTD (MESO)
About MESOBLAST LTD
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Market cap
- $1.8B
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $1.8B
- Shares outstanding
- 117.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jan 5, 2009
Mesoblast Ltd (MESO) Stock Price
- Trading 27% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review MESOBLAST LTD.
Write a review
News about MESOBLAST LTD
News & sentiment via Polygon.io
Mesoblast Ltd: frequently asked questions
Is Mesoblast Ltd an American company?
Mesoblast Ltd is a US-based company, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Is Mesoblast Ltd publicly traded?
Yes — Mesoblast Ltd is a publicly traded company. Its stock trades under the ticker symbol MESO on the NASDAQ.
What does Mesoblast Ltd do?
Mesoblast Ltd is an American Pharmaceuticals company in the Health & Beauty sector.
